GlassScriptPhysician profile
Anwar Ahmad
NPI 1598704819
$4,166.56
in general payments reported to CMS, 2019-2025
24 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $245 · 2021: $459 · 2022: $90.98 · 2023: $415 · 2024: $854 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,686 · Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,685.81 |
| Food and Beverage | $1,475.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,085.91 | 2024-2025 | Micra |
| Astrazeneca Pharmaceuticals LP | $498.09 | 2020-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $326.51 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $303.98 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.24 | 2021-2025 | Jardiance |
| Pfizer INC. | $146.67 | 2019-2024 | |
| Edwards Lifesciences Corporation | $143.70 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $126.20 | 2019-2021 | |
| Amgen INC. | $77.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $58.58 | 2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $49.10 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $32.93 | 2022-2023 | Verquvo |
| Kestra Medical Technology Services, INC. | $30.71 | 2024 | Assure Wcd |
| Abbott Laboratories | $27.60 | 2021 | |
| Amarin Pharma, INC. | $23.08 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.72 | 2021 | |
| Genzyme Corporation | $19.99 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.68 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.92 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.